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The published article contains several errors introduced during the production process. In the penultimate sentence of the Introduction, the web address, ClinicalTrials.gov incorrectly linked to a reference. The correct sentence is presented here:Furthermore, linagliptin is the first and so far only DPP-4 inhibitor to be evaluated in a randomized clinical trial designed to robustly assess renal outcomes: the ongoing Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA®; ClinicalTrials.gov: [NCT01897532](https://clinicaltrials.gov/ct2/show/NCT01897532)).In the captions to Figures 1 and 3, the reference citations attributed to statements of permission to reproduce were incorrect; the correct sources of the figures are presented here. Figure 1 was reproduced from reference \[18\]: Shi, S., Koya, D. and Kanasaki, K. (2016) Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair **9**, 1, <https://doi.org/10.1186/s13069-016-0038-0>Figure 3 was reproduced from reference \[107\]: Zeisberg, M. and Zeisberg, E.M. (2015) Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin. Kidney Int. **88**, 429--431, <https://doi.org/10.1038/ki.2015.175><https://doi.org/10.1038/ki.2015.175><https://doi.org/10.1038/ki.2015.175>Corrected online 8 January 2019.
